Form 4: Harvard Bioscience Interim CFO Acquires 100,000 Restricted Stock Units

Mark T. Frost, Interim CFO of Harvard Bioscience, Inc., acquired 100,000 restricted stock units on May 12, 2025, according to a Form 4 filing.

Summary

• On May 12, 2025, Mark T. Frost, the Interim CFO of Harvard Bioscience, Inc. acquired 100,000 restricted stock units.
• These restricted stock units will vest on May 12, 2026.
• Following the transaction, Frost beneficially owns a total of 125,000 shares, including the restricted stock units and 25,000 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock units granted to an executive. It doesn't inherently indicate positive or negative performance, but rather a part of compensation.

Positives

• The acquisition of restricted stock units by the Interim CFO could signal confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in the biotechnology and life sciences industry.

Stakeholder Impact

• The granting of restricted stock units aligns the executive's interests with those of the shareholders, potentially incentivizing performance.

Key Dates

Keywords

Form 4, Harvard Bioscience, HBIO, Restricted Stock Units, Beneficial Ownership, Mark T. Frost, Interim CFO, Equity Securities